Latest European Markets News

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.

Energy One Limited (ASX:EOL) reported a robust FY2026 with a 17% increase in recurring revenue and a 51% jump in net profit before tax, while preparing for a transformative acquisition of Gas Management Services Limited to deepen its European market presence.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

AML3D Limited surged to a record $12.5 million revenue in FY26, delivering its first half-year EBITDA profit and locking in a $29 million order book driven by US Defence contracts and UK market entry.

IODM Limited’s FY26 results show solid revenue gains led by UK education, but losses persist with a net deficiency in equity raising going concern questions.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Credit Clear Limited posted a 28% rise in FY26 revenue to $60 million, boosted by UK acquisitions and organic growth, while defending legal action by the ACCC.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

Camplify Holdings slashed its net loss by 95% in FY26, posting a second-half profit driven by cost cuts and the MyWay Mutual insurance launch, setting a foundation for growth in FY27.